share_log

Oppenheimer Reiterates Outperform on Corbus Pharmaceuticals, Maintains $22 Price Target

Benzinga ·  Aug 9, 2023 09:47

Oppenheimer analyst Jeff Jones reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and maintains $22 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment